PBYI Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 112160 min ago

@ $7.35

Išleistas: 14 vas. 2024 @ 22:31

Grąža: -33.20%

Ankstesnis signalas: vas. 13 - 22:35

Ankstesnis signalas: Pardavimas

Grąža: 18.17 %

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 20:50):

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally...

Stats
Šios dienos apimtis	168 583
Vidutinė apimtis	589 481
Rinkos kapitalizacija	236.70M
EPS	$0 ( 2024-02-29 )
Kita pelno data	( $-0.220 ) 2024-06-18
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	10.91
ATR14	$0.0130 (0.26%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Auerbach Alan H	Buy	6 577	Common Stock
2024-03-15	Auerbach Alan H	Buy	9 047	Stock Option (Right to Buy)
2024-02-12	Wong Alvin F	Buy	43 307	Common Stock
2024-02-12	Wong Alvin F	Buy	59 946	Stock Option (Right to Buy)
2024-02-12	Nougues Maximo F	Buy	43 307	Common Stock

INSIDER POWER
69.68
Last 99 transactions
Buy: 2 879 886 \| Sell: 561 464

Tūris Koreliacija

Ilgas: 0.21 (neutral)

Trumpas: 0.40 (neutral)

Signal:(47.597) Neutral

Puma Biotechnology Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Puma Biotechnology Inc Koreliacija - Valiuta/Žaliavos

0.04
( neutral )

0.00
( neutral )

-0.07
( neutral )

0.74
( moderate )

-0.24
( neutral )

Puma Biotechnology Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$235.64M
Bruto pelnas:	$172.96M (73.40 %)
EPS:	$0.460

FY	2023
Pajamos:	$235.64M
Bruto pelnas:	$172.96M (73.40 %)
EPS:	$0.460

FY	2022
Pajamos:	$228.00M
Bruto pelnas:	$172.90M (75.83 %)
EPS:	$0.0204

FY	2021
Pajamos:	$253.16M
Bruto pelnas:	$189.45M (74.84 %)
EPS:	$-0.720

Financial Reports:

No articles found.

Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Realaus laiko atnaujinimai Puma Biotechnology Inc [PBYI]

Upcoming Earnings Alert